Superdrol Inj 40 mg is an oil-based Methyldrostanolone injectable manufactured by Dragon Pharma and dosed at 40 mg/mL in a 10 mL vial.
Superdrol Inj 40 mg contains methyldrostanolone (also known as methasterone or Superdrol), a synthetic orally active anabolic-androgenic steroid viewed as a derivative of dihydrotestosterone and a C17α-alkylated form of drostanolone. This agent was never marketed as a prescription drug; instead, it is known as a designer steroid. It possesses a very pronounced anabolic effect with low androgenic activity, having an anabolic-to-androgenic ratio of 400:20.
In non-medical bodybuilding contexts, methyldrostanolone is commonly referenced for its rapid and pronounced effects on muscle fullness, strength, and overall physique transformation. The injectable formulation delivers the same active compound in an oil-based carrier, which some users prefer over oral administration. However, this compound carries significant hepatotoxic risk due to its C17α-alkylated structure, and published case reports have documented severe cholestatic liver injury associated with its use.
Methyldrostanolone is notable for its potency and the rapidity of its effects, but it is also associated with complete HPTA suppression even at low doses. The compound has been restricted by WADA both in and out of competition since 2006. Non-medical use for bodybuilding or performance enhancement falls outside any approved medical indication and carries substantial health risks.
Superdrol Inj 40 mg uses MCT oil as its carrier, providing an oil base for the methyldrostanolone formulation. The 40 mg/mL concentration is a high-strength presentation for this compound.
Methyldrostanolone is a C17α-alkylated DHT-derived designer anabolic steroid with exceptional potency and significant hepatotoxic potential. Its defining characteristics are its high anabolic-to-androgenic ratio and its complete suppression of endogenous testosterone production.
Methyldrostanolone (2α,17α-dimethyl-4,5α-dihydrotestosterone) is structurally a C17α-alkylated form of drostanolone, which itself is a DHT derivative. The 17α-methyl group confers oral bioavailability but also defines its classification among C17α-alkylated steroids, which are associated with hepatotoxicity. The compound binds to the androgen receptor and promotes anabolism in skeletal muscle with an anabolic-to-androgenic ratio of 400:20, indicating exceptionally high anabolic potency relative to androgenic effects.
Unlike many other anabolic steroids, methyldrostanolone does not aromatize to estrogen, as it is a DHT derivative. This means it does not cause water retention or gynecomastia when used alone. However, it is a potent suppressor of the hypothalamic-pituitary-gonadal axis, with complete HPTA suppression reported even at 10 mg per day.
Methyldrostanolone was never approved for human medical use and is classified as a designer steroid. It was brought to market in a clandestine fashion and has been associated with multiple case reports of severe cholestatic liver injury.
Methyldrostanolone is known for its rapid onset of effects, with users commonly reporting noticeable changes in muscle fullness and strength within the first week of use. In non-medical contexts, cycle lengths are typically limited to 2 to 4 weeks due to the compound's significant hepatotoxic potential. The injectable formulation may allow for slightly extended use compared to oral administration, though the C17α-alkyl group still confers hepatic exposure.
Dragon Pharma offers the oral version of this compound, Superdrol 10, which contains 10 mg of methyldrostanolone per tablet. The injectable Superdrol Inj 40 mg offers a higher concentration per mL and bypasses first-pass hepatic metabolism, though the C17α-alkyl group still carries hepatotoxic risk. For those seeking a less hepatotoxic oral option, Anavar 10 is commonly referenced in bodybuilding contexts, though it is significantly milder in potency.
In non-medical bodybuilding contexts, Superdrol is frequently stacked with a testosterone base such as Cypionate 250. Another injectable C17α-alkylated option is Anadrol Inj, though using multiple C17α-alkylated compounds concurrently is strongly discouraged due to compounded hepatic stress.
Published laboratory reports for Superdrol Inj 40 mg are shown below with the test date, measured concentration and percentage of the product's 40 mg/mL label claim.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every vial or production batch.
The information below is provided for educational reference only. Methyldrostanolone is a designer steroid that has never been approved for human medical use; non-medical use falls outside any approved indications and carries significant health risks.
In non-medical bodybuilding contexts, methyldrostanolone is commonly referenced in the range of 10–20 mg per day for oral use, with cycles limited to 2–4 weeks due to hepatotoxicity. The injectable formulation is sometimes referenced at similar daily totals, though the 40 mg/mL concentration means users typically require very small injection volumes. Some experienced users reference 20–30 mg per day, but these higher doses are associated with significantly increased side effect risk.
| Use Case | Common Reference Range | Administration Frequency |
|---|---|---|
| Beginner (non-medical) | 5–10 mg / day | Daily, possibly split |
| Intermediate (non-medical) | 10–20 mg / day | Daily, split doses |
| Advanced (non-medical) | 20–30 mg / day | Daily, split doses |
In non-medical bodybuilding contexts, Superdrol is frequently stacked with a testosterone base such as Cypionate 250. Because of its complete HPTA suppression, a test base is commonly referenced to maintain normal physiological function during the cycle. Cycle lengths are typically limited to 2–4 weeks, and users are strongly advised to avoid stacking multiple C17α-alkylated compounds concurrently.
Mid-cycle bloodwork, including a comprehensive metabolic panel and lipid panel at approximately week 2, is commonly referenced as a risk-reduction strategy when using this compound.
Methyldrostanolone is associated with significant hepatotoxic risk. Published case reports have documented severe cholestatic liver injury, with jaundice, pruritus, and elevated bilirubin levels presenting a median of 2 weeks after discontinuation. Acute kidney injury has also been reported alongside severe cholestasis.
Common management strategies referenced in non-medical contexts include liver support with NAC (1000–1200 mg), TUDCA (300–500 mg), and milk thistle (600–900 mg). Blood pressure and lipid profiles should also be monitored, as the compound can negatively affect cardiovascular markers. Mood irritability and libido fluctuations are also commonly referenced.
After completing a cycle with Superdrol Inj 40 mg, post-cycle therapy is essential. HPTA suppression is complete and rapid even at low doses. On a standalone run, PCT with a SERM such as Clomid or Nolvadex should begin 3–4 days after the last dose. On a test base, PCT timing is dictated by the injectable's half-life. Expect libido, mood, and strength to be down for 4–8 weeks post-cycle even with PCT, and bloodwork at week 4 post-PCT is commonly referenced to confirm recovery.
Dosing strategies, support compounds and recovery protocols should be adjusted based on experience level and bloodwork where possible. The information above is for educational reference and does not constitute medical advice.
Methyldrostanolone is a designer anabolic steroid that has never been approved for human medical use and is associated with severe hepatotoxic and renal risks. It is restricted by WADA both in and out of competition.
Methyldrostanolone was never marketed through legitimate channels for medicinal purposes and is classified as a designer steroid. It is a C17α-alkylated compound, a structural feature associated with significant hepatotoxicity. Multiple published case reports have documented severe cholestatic liver injury requiring hospitalization, with jaundice, pruritus, and elevated bilirubin levels presenting 1–2 months after starting the supplement. Acute kidney injury has also been reported alongside severe cholestasis.
Non-medical use for bodybuilding or performance enhancement falls outside any approved medical indication and carries substantial health risks. The compound is restricted by WADA both in and out of competition since 2006.
Use of methyldrostanolone for bodybuilding or performance enhancement falls outside any approved medical indication. Higher-than-physiologic exposure can increase the risk of serious hepatotoxic, renal, and cardiovascular complications.
Cholestatic liver injury is the published signature toxicity of methyldrostanolone. Case reports describe five young, previously healthy men presenting with cholestatic jaundice a median of 2 weeks after discontinuation of methasteron, with peak bilirubin levels ranging from 11 mg/dL to 51 mg/dL. Jaundice resolved after 8–12 weeks in most cases, with biopsy showing classic features of anabolic steroid-induced liver injury.
Acute kidney injury has been reported alongside severe cholestasis, likely from bilirubin-driven tubular damage. One case report described a 42-year-old man who developed jaundice and pruritus 7 weeks after starting Superdrol, with bilirubin 41.2 mg/dL, ALT 98 U/L, and creatinine 3.5 mg/dL, with both renal and liver injury resolving slowly over 4 months.
Cardiovascular effects include negative alterations in lipid profiles, with decreases in HDL cholesterol and increases in LDL. Mood irritability, libido fluctuations, and prolonged post-cycle crash are also commonly referenced. HPTA suppression is complete even at 10 mg per day.
Methyldrostanolone is contraindicated in individuals with pre-existing liver disease, including hepatitis, fatty liver with elevated enzymes, or prior drug-induced liver injury. Untreated hypertension and pre-existing dyslipidemia are also contraindications. Concurrent use with any other C17α-alkylated oral steroid is strongly discouraged due to compounded hepatic stress. Heavy alcohol use, acetaminophen abuse, or any hepatotoxic prescription medications should also be avoided. Women should avoid this compound entirely due to virilization risk and equivalent hepatotoxicity.
If methyldrostanolone is used in any context, mid-cycle bloodwork including a comprehensive metabolic panel and lipid panel at approximately week 2 is strongly recommended. If ALT exceeds 5 times the upper limit of normal or bilirubin rises, the cycle should be ended immediately. Blood pressure monitoring is also important given the cardiovascular effects of the compound. In non-medical bodybuilding contexts, bloodwork before, during, and after a cycle is commonly referenced as a risk-reduction strategy.
Keep the vial securely stored and protected from conditions that could compromise the product or container. Store at controlled room temperature and protect from light and moisture. Inspect the vial and solution before use and do not use a product that appears damaged, contaminated or otherwise abnormal.
Keep all medications and injectable products out of the reach of children. Follow the storage instructions provided with the product packaging.
Superdrol Inj 40 mg by Dragon Pharma is shipped in original manufacturer packaging with discreet, privacy-focused handling.
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details.
To verify your Superdrol Inj 40 mg product, use the security code on the vial label and cross-check it on the Dragon Pharma official site. Original Dragon Pharma packaging and batch-linked lab proof help reinforce product legitimacy. Given that Superdrol is a commonly counterfeited designer steroid, laboratory verification is particularly valuable for this compound.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Proper storage conditions help preserve formulation stability and overall product integrity throughout shelf life.
Store at controlled room temperature (15–25°C) and protect from excessive heat, moisture, and direct light. Maintaining stable conditions helps preserve the integrity of the oily formulation.
Keep the vial in its original packaging until use. Do not freeze. Before administration, inspect the solution and avoid use if it appears cloudy, discolored, contains particulate matter, or if the vial or seal is compromised.
Keep out of reach of children. Follow proper handling and sterile injection practices when administering the product.
Answers to common questions about Superdrol Inj 40 mg, methyldrostanolone, usage considerations, product strength and laboratory testing.
Superdrol Inj 40 mg contains methyldrostanolone, a designer steroid that was never marketed as a prescription drug. In non-medical bodybuilding settings, Superdrol Inj 40 mg is commonly referenced for rapid muscle fullness, strength gains, and physique transformation, though such use falls outside any approved medical indication and carries significant health risks.
In non-medical bodybuilding contexts, methyldrostanolone is typically referenced as being administered daily, with doses often split into two administrations. Because of its short active life, daily or twice-daily injection is commonly referenced for stable blood levels. The 40 mg/mL concentration means users typically require very small injection volumes.
Yes. HPTA suppression from methyldrostanolone is complete and rapid, even at 10 mg per day. In non-medical bodybuilding contexts, post-cycle therapy is essential after a Superdrol cycle. Agents such as Clomid or Nolvadex are commonly referenced for this purpose, and bloodwork at week 4 post-PCT is recommended to confirm recovery.
Methyldrostanolone binds to the androgen receptor with high affinity and promotes nitrogen retention and protein synthesis in skeletal muscle. It is a C17α-alkylated DHT derivative with an anabolic-to-androgenic ratio of 400:20, indicating exceptionally high anabolic potency relative to androgenic effects. Unlike testosterone, it does not aromatize to estrogen.
Methyldrostanolone is known for its rapid onset of effects. In non-medical contexts, users commonly report noticeable changes in muscle fullness and strength within the first week of use. The compound's effects are often described as rapid and pronounced, which is one reason it is popular despite its significant side effect profile.
Methyldrostanolone is widely considered one of the most potent anabolic steroids available, with an anabolic-to-androgenic ratio of 400:20. However, its potency comes with significant hepatotoxic risk and complete HPTA suppression. There is no universally "best" compound, and this one carries particularly high risk.
The primary difference is the administration route. Superdrol Inj 40 mg delivers methyldrostanolone via intramuscular injection, while oral preparations such as Superdrol 10 are taken by mouth. Both ultimately provide the same active compound, though the injectable form bypasses initial first-pass hepatic metabolism. However, the C17α-alkyl group still confers significant hepatotoxic risk regardless of route.
Superdrol Inj 40 mg contains methyldrostanolone, a DHT-derived C17α-alkylated designer steroid. Anadrol Inj contains oxymetholone, a different C17α-alkylated anabolic steroid. Both are hepatotoxic and should not be stacked together. They have different potency profiles and side effect characteristics.
A milligram amount cannot be classified as appropriate or excessive without considering the specific context, individual response, and other factors. In non-medical bodybuilding contexts, methyldrostanolone is commonly referenced in the 10–20 mg per day range, with cycles limited to 2–4 weeks. The 40 mg/mL concentration means that even small injection volumes deliver substantial doses. Such use falls outside approved indications.
Superdrol Inj 40 mg is labeled at 40 mg of methyldrostanolone per mL. It is supplied in a 10 mL vial, giving 400 mg of total labeled methyldrostanolone content per vial.
Yes. A published laboratory report dated October 5, 2024 measured Superdrol Inj 40 mg at 45.23 mg, equivalent to 113.08% of its 40 mg/mL label claim.
The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report and should not be interpreted as a measurement of every vial.
Methyldrostanolone is a C17α-alkylated compound, a structural feature associated with significant hepatotoxicity. Published case reports have documented severe cholestatic liver injury requiring hospitalization, with jaundice, pruritus, and elevated bilirubin levels. Acute kidney injury has also been reported alongside severe cholestasis. The compound also causes complete HPTA suppression even at low doses.